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Abstract
Background: Immune infiltration of the tumor microenvironment has been associated with improved survival for some
patients with solid tumors. The precise makeup and prognostic relevance of immune infiltrates across a broad spectrum of
tumors remain unclear.
Methods: Using mRNA sequencing data from The Cancer Genome Atlas (TCGA) from 11 tumor types representing 3485
tumors, we evaluated lymphocyte and macrophage gene expression by tissue type and by genomic subtypes defined within
and across tumor tissue of origin (Cox proportional hazards, Pearson correlation). We investigated clonal diversity of B-cell
infiltrates through calculating B-cell receptor (BCR) repertoire sequence diversity. All statistical tests were two-sided.
Results: High expression of T-cell and B-cell signatures predicted improved overall survival across many tumor types
including breast, lung, and melanoma (breast CD8_T_Cells hazard ratio [HR] ¼ 0.36, 95% confidence interval [CI] ¼ 0.16 to 0.81,
P ¼ .01; lung adenocarcinoma B_Cell_60gene HR¼0.71, 95% CI¼0.58 to 0.87, P ¼ 7.80E-04; melanoma LCK HR¼0.86, 95%
CI¼0.79 to 0.94, P ¼ 6.75E-04). Macrophage signatures predicted worse survival in GBM, as did B-cell signatures in renal
tumors (Glioblastoma Multiforme [GBM]: macrophages HR¼1.62, 95% CI¼1.17 to 2.26, P ¼ .004; renal: B_Cell_60gene
HR¼1.17, 95% CI¼1.04 to 1.32, P ¼ .009). BCR diversity was associated with survival beyond gene segment expression in
melanoma (HR¼2.67, 95% CI¼1.32 to 5.40, P ¼ .02) and renal cell carcinoma (HR¼0.36, 95% CI¼0.15 to 0.87, P ¼ .006).
Conclusions: These data support existing studies suggesting that in diverse tissue types, heterogeneous immune infiltrates
are present and typically portend an improved prognosis. In some tumor types, BCR diversity was also associated with
survival. Quantitative genomic signatures of immune cells warrant further testing as prognostic markers and potential
biomarkers of response to cancer immunotherapy.
The complex interplay between solid tumors and host immu-
nity has been widely studied but remains incompletely under-
stood. In multiple tumor types, tumor-infiltrating lymphocytes
(TILs) have been associated with clinical outcomes (1–8). For ex-
ample, CD8þ TILs have been shown to be favorably prognostic
in melanoma, colorectal, breast, ovarian, and non–small cell
lung cancer. In selected tumors, it has been demonstrated that
these CD8þ TILs are able to specifically kill tumor cells (9,10).
Several schemas have been developed to leverage immune infil-
tration as a prognostic factor (11,12). Solid tumors are thought
to cultivate an immunosuppressive microenvironment that
promotes exhaustion of TILs and induction of a protumor, in-
flammatory wound-healing response (13). This is supported by
data that regulatory T-cells (Treg), tumor-associated macro-
phages (TAMs), and/or myeloid-derived suppressor cells
(MDSCs) predict worse outcomes in melanoma, renal cell
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carcinoma, breast, ovarian, bladder, prostate, and non–small
cell lung cancer (14–16). The wide impact and clinical relevance
of the multifaceted tumor-associated immune response makes
it critical to develop a more thorough understanding of this
phenomenon.
Next-generation sequencing and large-scale genomics have
become critical to our understanding of human cancers.
Through efforts such as The Cancer Genome Atlas (TCGA)
Project, genomic data on a wide variety of tumors have become
available. By combining diverse datasets, groupings both within
and across tumor types have emerged (17). This has deepened
our understanding of distinctions within tumor types and high-
lighted similarities between previously distinct tumor types,
such as identification of the “squamous” genomic subtype,
which combines lung squamous, head and neck, and some
bladder cancers into a single group (17,18). While many tumor
types are thought to harbor prognostic TILs, the interplay be-
tween genomic subtype and the antitumor immune response
has not been adequately explored.
Cancer immunotherapy has been pursued as an alternative
or complement to cytotoxic chemotherapy and radiotherapy.
Inhibition of the immune checkpoint proteins CTLA-4, PD-1, and
PD-L1 reduces the ability of the tumor microenvironment to sup-
press host antitumor immunity (19–21), and immune checkpoint
inhibitors have shown clinical responses in diverse cancers (20–
24). As these and other immune-targeted therapies gain wide-
spread clinical usage, a key question is identification of tumor
characteristics that predict response. Evidence in melanoma and
bladder cancer suggests that responders may harbor clonally
restricted, antitumor TILs that are able to respond after immuno-
suppression has been lifted (23,25). In this work, we use mRNA-
seq data for a large number of diverse tumors to analyze the
prevalence and prognostic relevance of tumor-immune infiltrates
and evaluate the clonal diversity of tumor-infiltrating B-cells.
Methods
Datasets
The dataset used comprised mRNA-seq data from 3485 TCGA
tumors (see TCGA Data Portal at https://tcga-data.nci.nih.gov/
tcga/, CGHub at https://cghub.ucsc.edu/), which was originally
described in Hoadley, 2014, with the following modifications
(17). AML samples were removed. Data for 329 melanoma sam-
ples were added (26). All samples were assayed by mRNA-seq,
as described by the TCGA Research Network (27). Gene expres-
sion values were represented as RSEM data normalized within
each sample to the upper quartile of total reads (37). For gene
signature and hierarchical clustering analyses, gene expression
values were median-centered across all 3485 tumors. Genomic
subtypes within tissue types and TCGA Pan-Cancer Cluster of
Clusters Assignments (COCA) subtypes were obtained from pre-
vious publications of those TCGA tissue types (17,18,27–33). No
COCA subtype was assigned to melanoma samples, and thus
melanoma was assigned to its own group in COCA subtype
analyses (34).
Gene Signatures and BCR Expression and Diversity
Several immune gene signatures were previously developed by
unsupervised hierarchical clustering of mRNA-seq expression
data for 728 breast tumor samples (35). In addition to these,
other tumor-infiltrating lymphocyte and macrophage gene
signatures were obtained from published studies. Multiple sig-
natures were used for each cell type to reduce bias from individ-
ual gene lists and included: IGG_Cluster (36), B_Cell (37), B_Cells
(12), B_Cell_cluster (35), B_Cell_60gene (38), and TNBC_B_Cell
(39) are B/plasma cell signatures. T_Cell (37), T_Cells (12),
T_Cell_cluster (35), CD8 (37), CD8_cluster (35), LCK (40), and
TNBC_T-Cell (39) are T-cell signatures, with the CD8 and
CD8_cluster signatures specifically representing CD8þ T-cells.
MacTh1_cluster (35), CD68_cluster (35), Mac_CSF1 (41), and
Macrophages (12) are all macrophage/monocyte signatures. For
each signature, the mean expression of all genes in the signa-
ture was used as the signature score for a given tumor/patient.
Expression levels for all BCR gene segments, overall BCR gene
segment expression, and BCR diversity values were calculated
according to previously described methods (35).
Statistical Analysis
Gene signature expression levels were compared using one-way
analysis of variance (ANOVA). Correlations were evaluated us-
ing Pearson coefficient calculation. Univariate survival analyses
were performed by Cox proportional hazards modeling, with
each signature tested as a continuous variable. Multivariable
Cox proportional hazards models were used to evaluate the
prognostic value of individual gene expression signatures when
combined with tumor type/subtype information and clinical
variables. All multivariable survival analyses included one gene
expression signature, as well as patient age and pathologic tu-
mor size (T), node (N), and metastasis (M) stages. Pathologic T,
N, and M stages were binned into T1 vs T>1, N0 vs N> 0, and
M0 vs M>0 groups to reduce the number of variables in each
model and to standardize across tumor types. Multiple testing
correction was done by calculating q-values for each P value,
and statistically significant q-values were confirmed using the
Kaplan-Meier estimator and log-rank testing of high-expression
vs low-expression groups. All survival analyses were performed
in R version 2.13.1 using the “survival” package (42,43). To as-
sess the statistical significance of association between BCR di-
versity and survival, multivariable Cox proportional hazard
models were constructed for each tumor tissue type where vari-
ables included BCR gene segment expression, diversity, and the
expression*diversity interaction term. Separate models were fit
using the expression term alone, and statistical significance
was assessed by performing analysis of variance comparing the
full and reduced models using the likelihood ratio test imple-
mented in R (43). A P value of less than .05 was considered sta-
tistically significant, and all statistical tests were two-sided.
Results
Genomic Signatures of Immune Infiltration
in Human Cancer
To clarify the role of tumor-infiltrating immune cells in human
cancer, gene signatures associated with immune cell types were
evaluated in a diverse set of 3485 tumors representing 11 tumor
types. Signatures chosen were previously published as corre-
sponding to tumor-infiltrating immune cells in at least one solid
tumor type. A heat map of signature expression across all 3485
samples ordered by tissue type and genomic subtype showed
high expression across particular cancer types and subtypes
(Figure 1). Immune signature expression in general was highest
in the basal-like bladder, basal-like and human epidermal
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growth factor 2 (HER2)–enriched breast, immunoreactive ovar-
ian, and immune melanoma subtypes, as well as in the head
and neck, clear cell renal cell, lung adenocarcinoma, and lung
squamous tissue types.
While only the ovarian immunoreactive and melanoma im-
mune subtypes were defined with immune infiltration as a key
feature, immune infiltration often segregated by tumor genomic
subtype. Similarly, assignment by Cluster of Cluster Analysis
classification yielded differences in immune gene signature ex-
pression (Figure 2; Supplementary Figure 1, available online) (17).
Within all tumor types, immune gene signatures tended to be
positively correlated, with the average Pearson correlation above
.63 for all tumor tissue or COCA types (Figure 3). Signatures repre-
senting the same immune cell type in most cases were highly
correlated regardless of tissue of origin or COCA type. The lowest
intersignature correlation was among glioblastoma samples,
which showed low expression of lymphocyte-related gene signa-
tures and high expression of signatures related to macrophages
and other myeloid-derived cell types.
Prognostic Significance of Immune
Infiltration Signatures
Univariate survival analyses for immune signature expression
within tissue and COCA types are summarized in Table 1 and
Supplementary Table 1 (available online), with hazard ratios pro-
vided in Supplementary Tables 2 and 3 (available online). The
number of events and median follow-up times varied substan-
tially between tumor types. Almost all immune signatures tested
were prognostic in the complete set of 3485 samples. The breast,
head and neck, lung adenocarcinoma, melanoma, and endome-
trial groups showed improved survival among patients with tu-
mors scoring high for a variety of immune signatures (eg, breast
CD8_T_Cells hazard ratio [HR] ¼ 0.36, 95% confidence interval [CI]
¼ 0.16 to 0.81, P ¼ .01; head and neck B_Cell_Cluster HR¼ 0.82,
95% CI¼ 0.74 to 0.91, P ¼ 2.22E-04; lung adenocarcinoma B_Cell_
60gene HR¼ 0.71, 95% CI¼ 0.58 to 0.87, P ¼ 7.80E-04; melanoma
LCK HR¼ 0.86, 95% CI¼ 0.79 to 0.94, P ¼ 6.75E-04; endometrial
CD8_cluster HR¼ 0.71, 95% CI¼ 0.55 to 0.92, P ¼ .001). When sam-
ples were divided by COCA subtype, the LUAD-enriched, squa-
mous, UCEC, and melanoma subtypes showed improved survival
with high immune signature expression for at least four signa-
tures each (LUAD-enriched HR¼ 0.73/0.69/0.75/0.77, 95% CI¼ 0.63
to 0.86/0.58 to 0.82/0.61 to 0.92/0.64 to 0.92, P ¼ 1.32E-04/2.14E-05/.
006/.004, for IGG_Cluster/B_Cell_60gene/T_Cells/CD8_cluster;
squamous HR¼ 0.89/0.86/0.85/0.87, 95% CI¼ 0.83 to 0.96/0.78 to 0.
95/0.76 to 0.95/0.79 to 0.96, P ¼ .003/.003/.006/.004, for B_Cell_clus
ter/T_Cell_cluster/T_Cells/CD8_cluster; UCEC HR¼ 0.71/0.70/0.
69/0.71, 95% CI¼ 0.54 to 0.93/0.52 to 0.93/0.50 to 0.96/0.55 to 0.93,
P ¼ .01/.02/.03/.01, for TNBC_T-Cell/LCK/T_Cells/CD8_cluster; mel-
anoma HR¼ 0.61/0.86/0.86/0.80, 95% CI¼ 0.46 to 0.79/0.80 to 0.92/
0.79 to 0.94/0.71 to 0.91, P ¼ 2.09E-04/1.77E-05/6.75E-04/6.04E-04,
for B_Cell/B_Cell_60gene/LCK/Mac_CSF1). Signatures representing
lymphocytes more consistently predicted overall survival than
did other signatures; the lung adenocarcinoma, head and neck,
breast, and endometrial tumor types showed consistent prognos-
tic ability for lymphocyte signatures and a decreased association
between survival and macrophage signatures. Interestingly, in
clear cell renal cell carcinoma there was an association of B-cell
signature expression with worse survival (eg, IGG_Cluster HR¼ 1.
22, 95% CI¼ 1.08 to 1.39, P ¼ .002). Macrophage-related signatures
were less commonly prognostic though they were associated
with worse survival overall and within GBM (eg, Macrophages
HR¼ 1.62, 95% CI¼ 1.17 to 2.26, P ¼ .004).
Multivariable survival analyses of immune signatures were
performed for each tumor tissue type individually, incorporat-
ing patient age, pathologic stage, and signature expression
(Supplementary Tables 4-11, available online). Multivariable
modeling results largely supported the results seen in the uni-
variate survival models, with head and neck, lung adenocarci-
noma, and melanoma showing consistent prognostic benefit for
patients with high immune gene expression (eg, B_Cell_cluster
HR¼ 0.82/0.77/0.92, 95% CI¼ 0.73 to 0.91/0.65 to 0.93/0.86 to 0.98,
Figure 1. Concordant expression of genes from different immune cell types in specific solid tumor types and subtypes. Tumors are ordered by column according to tis-
sue type and subtype. Within signatures, genes are ordered by row by unsupervised hierarchical clustering across all patients. Log 2 gene expression is median-cen-
tered across all samples. IGG_Cluster, B_Cell, B_Cells, B_Cell_cluster, B_Cell_60gene, and TNBC_B_Cell are B/plasma cell signatures. T_Cell, T_Cells, T_Cell_cluster, CD8,
CD8_cluster, LCK, and TNBC_T-Cell are T-cell signatures, with the CD8 and CD8_cluster signatures specifically representing CD8þ T-cells. MacTh1_cluster,
CD68_cluster, Mac_CSF1, and Macrophages are all macrophage/monocyte signatures.
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P ¼ .005/3.30E-04/.01 for head and neck/lung adenocarcinoma/
melanoma). GBM, ovarian, and endometrial tumors were ex-
cluded from multivariable analyses within tissue types, as path-
ologic staging data were not available.
Prognostic BCR Gene Segment Expression
Previous investigations of TILs have suggested that many
tumors contain clonally restricted T- and/or B-cell infiltrates
(44–46), consistent with an antigen-driven response. As previ-
ously described, mRNA-seq data can be used to estimate the
relative clonal diversity of B-cell populations and discover as-
sociations between specific BCR gene segment expression and
improved survival (35). Given our prior results that B-cell gene
signature expression was more statistically significantly asso-
ciated with improved OS than either T-cell gene signature ex-
pression or the classical clinical prognostic variables of age
and lymph node involvement in breast cancer, and that spe-
cific BCR segments where expression was associated with OS
Figure 3. Correlation of lymphocyte infiltration signatures in tumors. In (A) all samples and (B-L) within samples in each tissue type, Pearson correlations are shown be-
tween all immune gene signatures.
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varied by tumor subtype, we were interested in exploring BCR
gene segment expression associations with survival in the
broader TCGA datasets. Figure 4A illustrates BCR gene seg-
ment expression across all tissue types, highlighting the same
tissue types identified by gene signature analysis. While BCR
expression was able to distinguish certain samples and tumor
types as high expressers, expression was high across multiple
BCR gene segments in such samples. To more specifically dis-
sect the importance of oligoclonal B-cell populations, we de-
termined if individual BCR gene segment expression was
associated with overall survival (Figure 4B). For melanoma and
head and neck squamous cell carcinoma, expression of the
majority of BCR gene segments was associated with prolonged
survival whereas in renal cell carcinoma and glioblastoma
multiforme most segments were associated with reduced
survival. There was a high degree of overlap of prognostic BCR
segments across tumor types in which many BCRs were prog-
nostic (melanoma, head and neck, glioblastoma, renal cell,
lung adenocarcinoma, and breast). To understand the statisti-
cal significance of individual BCR gene segment expression,
we assessed for each tumor type whether the number of prog-
nostic BCR segments exceeded the number of prognostic genes
expected by chance. To do this, we used a bootstrap resam-
pling approach by randomly choosing a subset of genes of the
same size as the number of total BCR gene segments (n¼ 1000
resamplings) and considering as the null distribution the 95%
confidence interval of the number of prognostic genes in the
resampling dataset. For seven tumor types, the number of
prognostic BCR segments exceeded the upper confidence in-
terval of the null distribution (Figure 4C).
Figure 4. B-cell receptor (BCR) gene segment expression and pattern of BCR gene segments, where expression was associated with overall survival by tumor type. A)
Unsupervised hierarchical clustering of average BCR gene segment expression by tissue type. B) Grid of BCR gene segments, where increased expression was statisti-
cally significantly associated with prolonged overall survival (OS; red) and gene segments associated with diminished OS (blue). C) Number of gene segments with sta-
tistically significant association with OS by tumor type. Cox proportional hazard models were built using Log10 gene expression for each gene segment. Null
distributions were estimated by bootstrap resampling (n¼ 1000) of 353 random genes and calculating the number where expression was associated with OS. Error bars
show the 95% bootstrap confidence interval.
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Figure 5 shows BCR gene segment expression and sequence
diversity for all samples and demonstrates the existence of a
high-expression, low-diversity group composed mainly of a sub-
set of melanoma, breast, head and neck, renal cell, and ovarian
tumors. To test the association of restricted BCR diversity with
survival, Cox proportional hazards models were built using BCR-
variable gene segment expression, diversity, and the interaction
term between expression and diversity. For each tissue type, this
model was compared with a reduced model containing BCR gene
segment expression as the sole variable. These models were
compared using analysis of variance to assess whether including
the diversity term in the full model provided a statistically signifi-
cantly more robust explanation of variance than the expression
term alone. This approach was used because B-cell gene segment
expression was highly correlated with B-cell gene signature ex-
pression, which was statistically significantly associated with
overall survival in multiple tumor types (Table 1). The results of
this analysis are shown in Figure 6. The full model was found to
be statistically significantly better at predicting survival in blad-
der, renal cell, and melanoma datasets. Decreased diversity was
associated with improved survival in melanoma (HR¼ 2.67, 95%
CI¼ 1.32 to 5.40, P ¼ .02). In contrast, decreased diversity was as-
sociated with diminished overall survival in renal cell carcinoma
(HR¼ 0.36, 95% CI¼ 0.15 to 0.87, P ¼ .006).
Discussion
Here we present several key aspects of a prognostically relevant
immune response, determined from mRNA-seq data across a
diverse set of human tumors. Patients with apparently benefi-
cial tumor-immune infiltrates had high levels of immune signa-
ture expression for several cell types, including cytotoxic and
helper T-cells, B/plasma cells, and macrophages/monocytes.
Among these highly infiltrated tumors, a subset contained a
highly expressed population of BCRs with lower sequence diver-
sity. Squamous and basal-like COCA subtypes showed in-
creased immune gene signature expression and prognostic
significance. The fact that these subtypes were defined compre-
hensively by global gene expression, protein levels, DNA copy
number, miRNA, and DNA methylation suggests that subtype-
defining features may be responsible for the shared immuno-
genic phenotype.
Most investigations into the role of TILs in human tumors
have focused on T-cells. Multiple studies have shown T-cell
TILs to be associated with response to immune checkpoint inhi-
bition and survival (23,47–49). This work adds to the growing
body of literature identifying T-cell TILs as a positive prognostic
feature. Less work has been done evaluating the role of B-cells
in solid tumors, though CD20 expression has been associated
with improved survival in breast and ovarian cancer (10,50).
Here we demonstrate that in all tumor types analyzed B-cell
gene expression, including expression of BCR gene segments,
was highly correlated with expression of T-cell genes. The
strong correlation of immune signature expression across dis-
tinct immune cell types illustrates that the tumor-immune in-
filtrate is diverse but somewhat predicable and consistent, with
a supportive role for B-cell TILs in the antitumor immune re-
sponse. The addition of B-cell clonal diversity analysis repre-
sents a novel aspect of tumor-immune research and highlights
the importance of B-cell TILs in diverse solid tumor types.
Our analysis of adaptive immune receptor repertoire diver-
sity is limited by evaluation of BCR repertoires alone. We fo-
cused on the BCR for one major technical reason. The diversity
estimate used here depends on the degree of sequence variation
within the immunoglobulin-variable loci generated by somatic
hypermutation. Because the TCR does not undergo somatic
hypermutation, we are not able to measure TCR diversity using
this approach. Our study is also limited by use of gene expres-
sion data to infer characteristics of the tumor-immune micro-
environment without companion cellular assays, which were
not obtainable from TCGA samples. Although the immune gene
signatures reported here have been published and well-
validated to correspond to specific cellular populations (12,35),
we were unable to evaluate abundances of more complex im-
mune cell phenotypes that may be important in tumor immu-
nobiology and accessable via multiparameter IHC or flow
cytometry. Nonetheless, our results are important in illustrating
the power of immune gene signature and BCR repertoire analy-
sis applied to a large and diverse RNA-seq dataset. It is unclear
whether immunohistochemistry-based methods of interrogat-
ing the tumor-immune microenvironment, such as the
Immunoscore (11), will outperform genomics methods for pro-
ductive biomarker development.
For most of the tumor types tested, immune infiltrates were
associated with improved survival; however, there were three
tumor types that were exceptions: colorectal adenocarcinoma,
clear cell renal cell carcinoma, and GBM. There are many stud-
ies indicating a beneficial role for TILs in human colorectal can-
cer (51–53). The failure to detect these associations in TCGA
data may have to do with the lack of adequate follow-up, low
event rate, and low number of patients with mismatch repair
gene mutations (54). In renal cell carcinoma, high expression of
B-cell signatures and decreased BCR diversity (consistent with
an antigen-driven response) predicted poor survival. Previous
work has suggested that this tumor type may contain abundant
Figure 6. Multivariable Cox proportional hazard modeling results for B-cell re-
ceptor (BCR) gene segment diversity vs overall survival. Each column indicates
one tumor tissue type. CoxPH survival models were fit with BCR variable gene
segment expression alone as an explanatory variable (Expression model) and in-
cluding both expression and diversity as explanatory variables (Expression &
Diversity model). Dark gray bars show change in LR v2 statistic between the
Expression model and the null model, and light gray bars show the change in LR
v2 statistic between the Expression model and the Expression & Diversity model
(ie, a measure of the extent of increased information included in the latter
model). Tumor types in which the Expression & Diversity model provided a sta-
tistically significantly better fit than the Expression model alone (P < .05 by LRT)
are indicated by *. All statistical tests were two-sided.
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regulatory B-cells (Breg), which may explain this finding.
Immune infiltration appeared to predict worse outcomes in
GBM as well. As in our data, infiltrating macrophages and/or
microglia often represent a large proportion of immune infil-
trates (55,56). The dominance of TAMs within the immune infil-
trate of GBM is consistent with a negative clinical impact.
In summary, for most solid tumor types, expression of im-
mune gene signatures predicted a more favorable outcome.
Analysis of potential clonal restriction suggests that in some tu-
mors with heavy immune infiltration, B-cell clonal restriction
adds prognostic information. This may be because of tumor an-
tigen–driven expansion of specific B-cell clones. Not all tumor
types show these common features, with counterexamples be-
ing GBM and clear cell renal cell carcinoma, where high immune
infiltration predicted a worse outcome. Thus, measures of im-
mune cell phenotypes, BCR (and potentially TCR) diversity, and
tissue type or subtype are needed to correctly interpret, and
likely act upon, these characteristics of the tumor microenvi-
ronment. High levels of pretreatment CD8þ TILs have correlated
with response to immune checkpoint inhibition in melanoma
and bladder cancer (23,47). It will be important to test whether
quantification of immune infiltrates using mRNA-seq predicts
clinical response to these and other immunotherapeutic strate-
gies going forward.
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